Journal article
An integrative model of physiological traits can be used to predict obstructive sleep apnea and response to non positive airway pressure therapy
RL Owens, BA Edwards, DJ Eckert, AS Jordan, SA Sands, A Malhotra, DP White, SH Loring, JP Butler, A Wellman
Sleep | Published : 2015
DOI: 10.5665/sleep.4750
Abstract
Study Objectives: Both anatomical and nonanatomical traits are important in obstructive sleep apnea (OSA) pathogenesis. We have previously described a model combining these traits, but have not determined its diagnostic accuracy to predict OSA. A valid model, and knowledge of the published effect sizes of trait manipulation, would also allow us to predict the number of patients with OSA who might be effectively treated without using positive airway pressure (PAP). Design, Participants and Intervention: Fifty-seven subjects with and without OSA underwent standard clinical and research sleep studies to measure OSA severity and the physiological traits important for OSA pathogenesis, respective..
View full abstractGrants
Awarded by National Heart, Lung, and Blood Institute
Funding Acknowledgements
This work was supported by the National Institutes of Health: R01HL102321 and K23HL105542. Dr. Edwards is supported by the National Health and Medical Research Council (NHMRC) of Australia's CJ Martin Overseas Biomedical Fellowship (1035115). Dr. Eckert was supported by the American Heart Association (10SDG3510018), an NHMRC of Australia Overseas Biomedical Fellowship (510392), and is currently supported by a NHMRC R.D. Wright Fellowship (1049814). Dr. Sands is supported by NHMRC Early Career Fellowship (1053201) and R.G. Menzies award. Dr. Jordan was supported by the American Heart Association (0840159N) and is currently supported by the Australian Research Council (FT100100203). Dr. Owens consults for Philips Respironics. Dr. Malhotra was a consultant for Philips Respironics, SHC, SGS, Apnex Medical, Pfizer, Apnicure, but has relinquished all outside personal income since May 2012. Dr. White was the chief medical officer for Philips Respironics until December 13, 2012, but is now the chief scientific officer for Apnicure Inc as of January 2013 and a consultant for Philips Respironics. Dr. Wellman has received consulting income from Apnicure, Philips Respironics, and Galleon. Dr. Wellman's interests were reviewed and are managed by the Brigham and Women's Hospital and Partners HealthCare in accordance with their conflict of interest policies. The other authors have indicated no financial conflicts of interest.